NZ506049A - Steroid derivatives; useful for selectively supplementing oestrogen deficiency in the central nervous system - Google Patents

Steroid derivatives; useful for selectively supplementing oestrogen deficiency in the central nervous system

Info

Publication number
NZ506049A
NZ506049A NZ506049A NZ50604999A NZ506049A NZ 506049 A NZ506049 A NZ 506049A NZ 506049 A NZ506049 A NZ 506049A NZ 50604999 A NZ50604999 A NZ 50604999A NZ 506049 A NZ506049 A NZ 506049A
Authority
NZ
New Zealand
Prior art keywords
useful
nervous system
central nervous
alkyl
independently
Prior art date
Application number
NZ506049A
Inventor
Vladimir Patchev
Michael Oettel
Ina Thieme
Sigfrid Schwarz
Wolfgang Romer
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998121831 external-priority patent/DE19821831A1/en
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Publication of NZ506049A publication Critical patent/NZ506049A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The steroids of the formula shown are useful for selectively supplementing estrogen deficiency in the central nervous system without affecting other organs or systems. The variables are defined as follows: R1 is H, -OH, or alkoxy; R2 is H, alkyl, acyl, or -SO2NR10R11 (where R10 and R11 are independently H or alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or morpholino ring); R3 is H or -OH; R4 is H, -OH, or alkyl; R5 and R6 are independently H or halogen; R7 is H or methyl; R8 is H, -OH, =O, or a group of formula -CR12R13 (in which R12 and R13 are independently H or halogen); R9 is methyl or ethyl; Z is a C,C double bond or an optionally substituted cyclopropane ring; The >CR5R6 is either in the a or b position, R7 being in the b position if >CR5R6 is in the a position, and vice versa.
NZ506049A 1998-02-20 1999-02-10 Steroid derivatives; useful for selectively supplementing oestrogen deficiency in the central nervous system NZ506049A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19807264 1998-02-20
DE1998121831 DE19821831A1 (en) 1998-05-15 1998-05-15 Selectively supplementing estrogen deficiency in the central nervous system, using 14,15-cyclopropano estrane steroid compounds
PCT/DE1999/000353 WO1999042108A1 (en) 1998-02-20 1999-02-10 Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system

Publications (1)

Publication Number Publication Date
NZ506049A true NZ506049A (en) 2002-09-27

Family

ID=26044035

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ506049A NZ506049A (en) 1998-02-20 1999-02-10 Steroid derivatives; useful for selectively supplementing oestrogen deficiency in the central nervous system

Country Status (24)

Country Link
EP (1) EP1056460B1 (en)
JP (1) JP2002503694A (en)
KR (1) KR20010041107A (en)
CN (1) CN1291102A (en)
AT (1) ATE252388T1 (en)
AU (1) AU739071C (en)
BG (1) BG104689A (en)
BR (1) BR9909205A (en)
CA (1) CA2321498A1 (en)
CZ (1) CZ291764B6 (en)
DE (1) DE59907446D1 (en)
EA (1) EA002707B1 (en)
EE (1) EE03906B1 (en)
HU (1) HUP0100742A3 (en)
ID (1) ID27069A (en)
IL (1) IL137727A0 (en)
IS (1) IS5571A (en)
NO (1) NO20004153L (en)
NZ (1) NZ506049A (en)
PL (1) PL342313A1 (en)
SK (1) SK12152000A3 (en)
TR (1) TR200002400T2 (en)
UA (1) UA57830C2 (en)
WO (1) WO1999042108A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253318T3 (en) * 2001-11-07 2006-06-01 Schering Ag IN VITRO LIGAND CROSSING OF THE STROGEN RECEIVER.
CN112189624A (en) * 2020-09-08 2021-01-08 山东第一医科大学(山东省医学科学院) Method for constructing and identifying female AD model by using receptor gene silencing technology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
DE4239946C2 (en) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estrane derivatives with a 14alpha, 15alpha-methylene group and process for their preparation
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4338314C1 (en) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage
DE4429397C2 (en) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
DE19524937A1 (en) * 1995-07-08 1997-01-09 Jenapharm Gmbh Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage and for drug substitution in men
WO1997003661A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Incorporated Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells

Also Published As

Publication number Publication date
PL342313A1 (en) 2001-06-04
EP1056460B1 (en) 2003-10-22
CN1291102A (en) 2001-04-11
EE200000477A (en) 2001-12-17
KR20010041107A (en) 2001-05-15
AU2920999A (en) 1999-09-06
CZ291764B6 (en) 2003-05-14
JP2002503694A (en) 2002-02-05
DE59907446D1 (en) 2003-11-27
BG104689A (en) 2001-04-30
EA002707B1 (en) 2002-08-29
CZ20002938A3 (en) 2001-01-17
WO1999042108A1 (en) 1999-08-26
TR200002400T2 (en) 2000-11-21
EP1056460A1 (en) 2000-12-06
CA2321498A1 (en) 1999-08-26
ATE252388T1 (en) 2003-11-15
NO20004153L (en) 2000-10-09
HUP0100742A3 (en) 2002-07-29
UA57830C2 (en) 2003-07-15
IL137727A0 (en) 2001-10-31
ID27069A (en) 2001-02-22
EA200000858A1 (en) 2001-04-23
IS5571A (en) 2000-07-24
SK12152000A3 (en) 2001-02-12
BR9909205A (en) 2000-11-14
EE03906B1 (en) 2002-12-16
NO20004153D0 (en) 2000-08-18
HUP0100742A2 (en) 2001-09-28
AU739071C (en) 2002-04-11
AU739071B2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
TW347387B (en) Piperidine derivatives
DK0639186T3 (en) Taxol derivatives
NO20002676D0 (en) Androgenic steroid compounds and a process for the preparation and use of the same
AU576199B2 (en) Beta-carboline derivatives
NZ506049A (en) Steroid derivatives; useful for selectively supplementing oestrogen deficiency in the central nervous system
DK0988312T3 (en) 17beta-allyloxy (thio) alkyl androstane derivatives for modulating meiosis
DK1163258T3 (en) Derivatives of 22R-hydroxycholesta-8,14-diene for the inhibition of meiosis
ES484683A1 (en) Tetrahydrothiopyrano[2,3-b]indole derivatives
GB2020280A (en) 4,5-Dihydroimidazol-Z-yl Amino Substituted Isoquinolines
UA41890C2 (en) process for the preparation of derivatives of 2-perfluoroalkyl-3-oxazoline-5-on (variants), perfluoroalkanoylaminonitrile intermediary compounds
FI964278A0 (en) Process for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives
BG106281A (en) New 2,3-benzodiazepine derivatives
TW358087B (en) Method for preparing carbamoylmethylurea derivatives
DK1137660T3 (en) 22S-hydroxycholesta-8,14-diene derivatives with meios regulating activity
DE69516715T2 (en) PREPARATION OF N- (3-HALOPROPYL) IMINOSTILLE AND ITS REALIZATION IN OPIPRAMOL
TW254937B (en) Benzocycloheptene derivative and process for preparation thereof
YU151591A (en) PROCESS FOR ETHYNYLATION OF 17-KETOSTEROIDS
NZ510556A (en) General epoxidation reaction for compounds with olefinic double bonds especially for synthesis for epoxymexrenone

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)